Asset Details
Do you wish to reserve the book?
Antibacterial properties of the pituitary adenylate cyclase-activating polypeptide: A new human antimicrobial peptide
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Antibacterial properties of the pituitary adenylate cyclase-activating polypeptide: A new human antimicrobial peptide
Do you wish to request the book?
Antibacterial properties of the pituitary adenylate cyclase-activating polypeptide: A new human antimicrobial peptide
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Antibacterial properties of the pituitary adenylate cyclase-activating polypeptide: A new human antimicrobial peptide
2018
Overview
The Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP), a polycationic, amphiphilic and helical neuropeptide, is well known for its neuroprotective actions and cell penetrating properties. In the present study, we evaluated the potent antibacterial property of PACAP38 and related analogs against various bacterial strains. Interestingly, PACAP38 and related analogs can inhibit the growth of various bacteria including Escherichia coli (JM109), Bacillus subtilis (PY79), and the pathogenic Burkholderia cenocepacia (J2315). Investigation of the mechanism of action suggested that a PACAP metabolite, identified as PACAP(9-38), might indeed be responsible for the observed PACAP38 antibacterial action. Surprisingly, PACAP(9-38), which does not induce haemolysis, exhibits an increased specificity toward Burkholderia cenocepacia J2315 compared to other tested bacteria. Finally, the predisposition of PACAP(9-38) to adopt a π-helix conformation rather than an α-helical conformation like PACAP38 could explain this gain in specificity. Overall, this study has revealed a new function for PACAP38 and related derivatives that can be added to its pleiotropic biological activities. This innovative study could therefore pave the way toward the development of new therapeutic agents against multiresistant bacteria, and more specifically the Burkholderia cenocepacia complex.
Publisher
Public Library of Science,Public Library of Science (PLoS)
Subject
/ Analogs
/ Animals
/ Anti-Bacterial Agents - chemistry
/ Anti-Bacterial Agents - pharmacology
/ Bacteria
/ Burkholderia cepacia complex - growth & development
/ E coli
/ Humans
/ Medicine and Health Sciences
/ Multidrug resistant organisms
/ Pituitary adenylate cyclase-activating polypeptide
/ Pituitary Adenylate Cyclase-Activating Polypeptide - chemistry
/ Pituitary Adenylate Cyclase-Activating Polypeptide - pharmacology
/ Protein Structure, Secondary
